


CURRICULUM VITAE
YUSUKE NAKAMURA, MD, PhD

CURRENT POSITION

Director, Cancer Precision Medicine Center
Japanese Foundation for Cancer Research
3-8-31 Ariake, Koto-ku, Tokyo 135-8550, JAPAN
Email: yusuke.nakamura@jfcrc.or.jp
Phone: +81-3570-0458



ACADEMIC QUALIFICATION

- August 1984 Doctor of Philosophy in Molecular Genetics, Osaka University, Japan. Research dissertation: "Sequences of cDNAs for human salivary and pancreatic alpha-amylases"
- May 1977 Medical Doctor's License in Japan
- March 1977 Graduated from Osaka University Medical School

CAREER HISTORY

- 2012 April-present
Professor, Department of Medicine, Section of Hematology/Oncology,
Professor, Department of Surgery
Deputy Director, Center for Personalized Therapeutics
The University of Chicago
- 2011 January-December **Special Advisor to the Japanese Cabinet**, Secretary General,
Office of Medical Innovation, Cabinet Secretariat, Government of Japan
- 2005 April-2010 March **Director**, RIKEN Center for Genomic Medicine
- 2000 April-2005 March **Group leader for Genotyping**, RIKEN SNP Research Center
- 1995 April – 2011 January **Director**, Human Genome Center, Institute of Medical Science,
The University of Tokyo
- 1994 October – 2012 March **Professor**, Laboratory of Molecular Medicine, Institute of
Medical Science, The University of Tokyo
- 1995 April – 2000 March **Head**, Division of Genome Analysis, Cancer Institute, Tokyo
- 1996 April - 1999 March **Professor**, Department of Clinical Genetics, Osaka University
School of Medicine
- 1989 April - 1995 March **Head**, Biochemistry Department, Cancer Institute, Tokyo
- 1989 January - 1989 August **Senior Associate**, Howard Hughes Medical Institute, University
of Utah
- 1987 September - 1989 August **Research Assistant Professor**, Department of Human
Genetics, University of Utah
- 1984 October - 1988 December **Research Associate**, Howard Hughes Medical Institute,
University of Utah
- 1981 April - 1984 October, **Research Fellow**, Institute for Molecular and Cellular Biology,
Osaka University
- 1977 May - 1981 March, Second Department of Surgery, Osaka University School of
Medicine

AWARDS

- 1991 Honorary Citizenship, The State of Maryland, USA
- 1992 Princess Takamatsu Cancer Research Award
- 1993 The Research Award of Japanese Foundation for Cancer Research
- 1995 The Award of the Japanese Society of Human Genetics
- 1996 Takeda Medical Prize
- 2000 Keio Medical Science Prize
- 2002 The Tomizo Yoshida Award of the Japanese Cancer Association
- 2004 The Medal with a Purple Ribbon (for contributions to education and culture)
- 2006 Bulgarian Academy of Medical Science, Foreign Member
- 2010 Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research (HUGO)
- 2011 Member, Association of American Physicians (AAP)
- 2011 Honorary Professor, Harbin Medical University
- 2011 IPIT Award
- 2013 Honorary Professor, Taipei Medical University
- 2014 Thomson Reuters Highly Cited Researcher

RESEARCH INTERESTS

- (1) **Molecular characterization of cancer-specific enzymes**, such as (a) MELK (maternal embryonic leucine zipper kinase) that are involved in the maintenance of cancer stem cells, (b) TOPK (T-lymphokine-activated killer cell-originated protein kinase) that plays a critical role at the final step of cytokinesis, (c) GALNT6 (Polypeptide N-acetylgalactosaminyltransferase 6) that is an enzyme involved in various carcinogenesis processes as well as (d) various methyltransferases that modify histones and non-histone proteins involved in carcinogenic pathways. Using such information, we have begun collaborating with pharmaceutical companies in order to screen for and develop drugs that will target these cancer-specific molecules.
- (2) **Characterization of the immune responses** in patients who were treated with cancer peptide vaccines, those who developed GVHD (Graft-versus-host disease) after bone marrow transplantation, those who are treated with anti-cancer drugs or anti-immune checkpoint antibody, and those who have autoimmune diseases, by means of high-throughput sequencing of T cell and B cell receptors (TCR and BCR) (immunogenomics or immunopharmacogenomics).
- (3) **Screening of neoantigens derived from somatic mutations in cancer cells**. We have been working on cancer peptide vaccines derived from cancer-testis or oncofetal proteins with oncogenic functions and high immunogenicity (oncoantigen) in the last decade. Since peptides containing a missense mutation are truly cancer-cell specific and expected to have immunogenicity (neoantigens), we are evaluating immune responses induced by these peptide epitopes.

The ultimate goals of our laboratory are to develop novel molecularly-targeted anti-cancer drugs and to establish the personalized treatment of cancer patients whereby they are treated with a targeted drug(s) which is not only effective but also has a minimum risk of adverse reactions. In the past five years, we have achieved multiple very important accomplishments.

PUBLICATIONS (AS OF 2016)

Journal	Total
Am. J. Human Genetics	34
Biochem Biophys Res Communications	16
British Journal of Cancer	13
Cancer	6
Cancer Research	115
Cancer Science	53
Cell	2
Clinical Cancer Research	35
Cytogenetics Cell Genetics	59
Genes Chromosomes and Cancer	44
Genomics	84
Human Genetics	34
Human Molecular Genetics	60
Human Mutation	12
Int J Cancer	13
Int J Oncology	30
J Clinical Oncology	3
J of Human Genetics	124
Lancet	6
Mol Cancer Research	1
Molecular Cell	1
Nature	17
Nature Cell Biology	2
Nature Communications	4
Nature Genetics	70
Neoplasia	16
New Eng. J. Med.	7
Oncogene	51
Oncolmmunology	5
Oncotarget	11
Pharmacogenetics and Genomics	9
Proc. Natl. Acad. Sci. USA	8
Science	11
Science Translational Medicine	1
Others	453
Total	1411

Sus trabajos se han citado más de 140,000 veces en la literatura científica .
<http://scholar.google.com/citations?user=dDQevDQAAAAJ&hl=en&oi=ao>

Nakamura's Profile in Nature: <https://www.nature.com/articles/nm0604-560>